Based on the preclinical results of DNMT inhibitors or HDAC inhibitors, epigenetic drugs are undergoing clinical trial investigations for the treatment of recurrent resistant ovarian cancer [136]. The gene discussed is DNMT1; the disease is ovarian cancer.